NEW YORK (GenomeWeb News) – Bruker today provided updated financial guidance for fiscal year 2009, saying in a presentation at the Thomas Weisel Partners Healthcare Conference in Boston that it expects a year-over-year revenue decline of approximately 2 percent.

The firm had previously said that it expected flat to a low single-digit decline in revenues for the year.

Bruker also said that it is not likely to meet its previous goal of improving upon its 2008 earnings per share of $.45.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.